Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

2-iminobiotin - Neurophyxia

Drug Profile

2-iminobiotin - Neurophyxia

Alternative Names: 2-IB; 2-Iminobiotin; Neufix

Latest Information Update: 28 Sep 2017

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Neurophyxia
  • Developer Neurophyxia; University Medical Center Utrecht
  • Class Imidazoles; Neuroprotectants; Pentanoic acids; Small molecules
  • Mechanism of Action Nitric oxide synthase type I inhibitors; Nitric oxide synthase type II inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Asphyxia

Most Recent Events

  • 28 Sep 2017 University Medical Centre Utrecht and Neurophyxia completes a phase II trial in Asphyxia (In infants) in Netherlands (IV), before September 2017 (EudraCT2014-004265-25)
  • 23 May 2017 Neurophyxia terminates a phase II trial in Asphyxia (In neonates) because recruitment too slow and site decided to use hypothermia (exclusion criteria) in Turkey and Lithuania (IV) (NCT01626924)
  • 14 Sep 2016 Phase-II clinical trials in Asphyxia (In neonates) in Congo (IV) (EudraCT2015-003063-12)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top